Lantern Pharma Initiates Phase 1 Trial for LP-284: Pioneering AI-Driven Cancer Therapies

Lantern Pharma Inc. has initiated a groundbreaking Phase 1 clinical trial, marking a significant advancement in the fight against cancer. The trial focuses on evaluating the investigational new drug LP-284 in patients battling relapsed or refractory non-Hodgkin’s lymphoma (NHL), including mantle cell lymphoma (MCL) and double-hit lymphoma (DHL), among other high-grade B-cell lymphomas (HGBL), as well as select solid tumors and sarcomas. Leveraging their proprietary AI and machine learning platform, RADR®, which is poised to surpass 100 billion data points in 2024, Lantern Pharma has swiftly uncovered and accelerated indications for LP-284 and other promising drug candidates.

Panna Sharma, President and CEO of Lantern Pharma, expressed confidence in LP-284's potential to revolutionize treatment options for patients with challenging genomic signatures, emphasizing the company's unwavering dedication to advancing AI-driven therapies to benefit those in need. This milestone underscores Lantern Pharma's commitment to innovation and its mission to transform the landscape of cancer care.